



Testicular germ-cell tumours and penile squamous cell carcinoma: Appropriate management makes the difference



Nicola Nicolai ^{a, b, *}, Davide Bionni ^{a, b}, Mario A. Catanzaro ^{a, b}, Maurizio Colecchia ^c, Annalisa Trama ^d, RARECAREnet Working Group¹

^a Testis Surgery Unit, Milan, Italy

^b Urology Unit, Milan, Italy

^c Pathology Department, Milan, Italy

^d Evaluative Epidemiology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy

ARTICLE INFO

Article history:

Received 16 September 2017

Received in revised form

8 January 2018

Accepted 6 February 2018

Available online 14 February 2018

Keywords:

Rare diseases

Testicular neoplasms

Neoplasms

Germ cell and embryonal

Penis neoplasms

Squamous cell

Carcinoma

Survival

Tertiary care centres

Community network

Europe

ABSTRACT

Germ-cell tumours (GCT) of the testis and penile squamous cell carcinoma (PeSCC) are a rare and a very rare uro-genital cancers, respectively. Both tumours are well defined entities in terms of management, where specific recommendations - in the form of continuously up-to-dated guide lines-are provided.

Impact of these tumour is relevant. Testicular GCT affects young, healthy men at the beginning of their adult life. PeSCC affects older men, but a proportion of these patients are young and the personal consequences of the disease may be devastating.

Deviation from recommended management may be a reason of a significant prognostic worsening, as proper treatment favourably impacts on these tumours, dramatically on GCT and significantly on PeSCC.

RARECAREnet data may permit to analyse how survivals may vary according to geographical areas, histology and age, leading to assume that non-homogeneous health-care resources may impact the cure and definitive outcomes. In support of this hypothesis, some epidemiologic datasets and clinical findings would indicate that survival may improve when appropriate treatments are delivered, linked to a different accessibility to the best health institutions, as a consequence of geographical, cultural and economic barriers.

Finally, strong clues based on epidemiological and clinical data support the hypothesis that treatment delivered at reference centres or under the aegis of a qualified multi-institutional network is associated with a better prognosis of patients with these malignancies.

The ERN EURACAN represents the best current European effort to answer this clinical need.

© 2018 Published by Elsevier Ltd.

Introduction

Among rare solid tumour of the male genital tract, testicular and penile cancers deserve a special interest due to their particular characteristics, although they show significant epidemiological differences.

Testicular tumours basically affect young men between 20 and 40 year-old, at the beginning or in full employment, social and affective life [1–5]. The annual incidence of testicular and para-testicular tumours is 3.29 (95% CI 3.27–3.32) cases per 10⁵

individuals, corresponding to 16,061 new cases in 2013 in EU28 [6]. The vast majority of these tumours are germ-cell tumours (GCT), as para-testicular adenocarcinoma and sex stromal tumours, display a crude incidence of only 0.001 and 0.02 × 10⁵ individuals [6], respectively. Following histological diagnosis, clinical decisions are crucial. Prognosis of GCT dramatically changed in the eighties of the past century, following the introduction of extremely effective drugs as cisplatin and etoposide, which allowed a cure for more advanced cases. Surgery evolved accordingly, and the most important and crucial intervention remains retroperitoneal lymph-node dissection (RPLND), which is usually indicated after completion of chemotherapy in non-seminoma, in very selected cases in seminoma and in some patients before chemotherapy in non-seminoma [1–4].

* Corresponding author. Testis Surgery Unit, Via Venezian, 1-20133, Milan, Italy.
E-mail address: nicola.nicolai@istitutotumori.mi.it (N. Nicolai).

¹ RARECAREnet Working Group collab authors are listed in appendix.

Penile cancer usually affects men between the 5th and the 8th decades, associates with local chronic inflammation or with human papillomaviruses (HPV) infection of some subtypes (mainly HPV 16, 18, 30 and 33) [7,8]. In Europe, the annual crude incidence rate of penile cancer is 0.66 (95% CI 0.65–0.67) cases per 10⁵ individuals, and equals to 3887 new cases in 2013 in EU28 [6]. Almost all penile cancers are penile squamous cell cancer (PeSCC), as adenocarcinoma had a crude incidence rate of 0.01. The prognosis of this disease is favourable in early stages, the most frequent, while it remains dismal in advanced disease, as no highly effective medical treatment is available. Surgery (i.e. inguinal and pelvic lymph-node dissection) remains crucial for the staging and the cure, as early detected small nodal metastases may be cured in more than 60% of cases at 5 years [7–10].

In common, GCT of the testis [1–4] and PeSCC [7,8] have defined recommendations, summarized by different and consistent guidelines, both in the diagnosis and in the treatment. The hypothesis is that a treatment not delivered according to the guidelines and by untrained professionals, may dramatically worsen the prognosis of these diseases.

This review discusses the burden of these two rare cancers, in term of frequency and outcome, focuses on the crucial points for diagnosis and treatments and sustains ongoing European efforts to standardize management.

Diagnosis

Clinical presentation

- a GCT of the testis. Usual presentation is a tenderless intrascrotal mass, with no or just moderate pain. Many patients currently present with a small lesion identified by scrotal ultrasound. Although an increasing information pressure disseminates the importance of auto-palpation in the young men, many patients still present with very large testicular masses, which may associate with a greater risk of an advanced disease.
- b PeSCC. Initial lesions are usually painless. Cultural heritage may impact on the individual attitude to access visit for a genital lesion. Diagnosis is often delayed due to patient modesty or due to wrong clinical diagnosis.

Histological diagnosis

- a GCT of the testis
 - i Recently, the International Society of Urological Pathology (ISUP) held the *Testicular Cancer Consultation Conference* and produced recommendations to be followed for standardize pathology [10]. The most critical issues received a recommendation, and often the question of a central review is called in. An Italian study showed that up to the early 2000's, half of the reports regarding stage I non-seminoma patients did not contain the information about vascular invasion [11]. Moreover, 27% of cases on review at a central pathology laboratory were reclassified as having vascular invasion, while 19% were reclassified as not having vascular invasion [11]. Since then, an extensive informative campaign conducted by the Italian Germ Cell Testicular Tumour Study Group [12], was able to reduce the number of reports with lacking information on vascular invasion.
 - ii Intra-operative diagnosis through frozen sections examination. Most diagnoses occur following ultrasound examination that reveals a small testicular hypoechoic lesion (<10 mm). The diagnostic pathway often includes surgical exploration and

open biopsy [13]. This pathway may spare a useless orchidectomy in case of benign lesions. An experienced pathologist can provide better performance in terms of accordance with definitive pathology [14]. Wrong intra-operative diagnoses may lead to useless orchiectomy or to a re-operation.

- iii An emerging interest concerns malignant transformation of teratoma (TMT). Cellular atypia of epithelial and mesenchymal elements in teratomatous metastases of patients treated with cisplatin-based chemotherapy for non-seminoma have been frequently found, which does not necessarily imply a different clinical outcome. Presence of only the expansive growth of the somatic malignant proliferation is a significant feature for the diagnosis of a TMT [15]. Although we have not an evidence supporting the need of an expert pathologist to assure the diagnosis of TMT, the complex evaluation criteria are intuitively a reason to recommend a second opinion review, in order to reduce misdiagnoses (including over-diagnoses).

TMT is rare, but associates with a worse prognosis than usual GCT. Moreover, the role of surgery both as post-chemotherapy option and as primary treatment (RPLND) in early stages of disease is commonly recommended, as it is associated with a better outcome [16].

- b PeSCC. The recent 2016 WHO classification on penile cancer deeply changed [17]. Most previous classifications were morphology-based. The current one presents a new classification based on clinic-pathologic distinctiveness and relation to HPV infection, which may be suspected by the analysis of p16 [18]. Some histological PeSCC variants associate with different clinical behaviour. Some have more favourable course than usual type, and deserve a more conservative treatment. Other, as sarcomatoid, basaloid and acantholytic SCC may have a rapid spread, sometime skipping inguinal nodes, and must require more aggressive treatment since the first diagnosis. A UK experience [19] showed that after histology review, pathology diagnoses significantly changed, with 31% of cases receiving a reclassification. The changes were deemed to be critical in 60.4% cases: some patients required more extensive and invasive treatment for local penile cancer management, while a change to a more conservative treatment approach in the pathologically downgraded group was provided in some cases.

Although no proof supports a different survival according to central review Vs initial report, it is intuitive that an adequate sampling and expert examination may give more detailed information about variants, invasion and extent of invasion beyond *lamina propria*, which play a prognostic role and may permit organ preservation and better quality of life in many patients.

Treatment of primary tumour

- 1 GCT of the testis
 - a Radical orchiectomy is the standard surgery for testicular GCT. Actually, about 90% of these simple surgeries are performed in primary care hospitals. We have no evidence that centralization of orchiectomy may produce any impact on the outcome of these patients.
 - b Partial orchiectomy. This procedure is called in for mono-orchid patients, where maintaining a sufficient amount of testicular parenchyma ensures the preservation of patient's own body image and of endocrine function. This procedure needs precise surgical steps, although it is not considered technically difficult. It requires a cautious evaluation of the preoperative functional

aspects, the patient expectations in terms of paternity and residual function; as a consequence dedicated endocrinologists and/or andrologists are advised [20].

2) PeSCC. Most early PeSCC may require conservative treatments. Laser excisions or surgical excision followed by glans resurfacing and - in some cases - Mohs surgery, represent documented effective alternatives with different indications and chances [21]. In a large mono-institutional series, patients treated with penile preservation showed no significant difference in survival compared to patients treated with partial amputation after adjusting for relevant co-variables [22]. Due to the rarity of disease, such procedures usually require dedicated surgeons, with a specific expertise.

Patients with recurrent disease or more advanced stage, need glanssectomy or amputation. As the primary treatment of high-risk primary tumours temporally coincides with the management of inguinal nodes, which is the key treatment in PeSCC management (see next paragraph on staging), it is advisable to plan the initial surgery in experienced centres.

Staging following initial surgery

- 1) GCT of the testis. Following orchiectomy, staging of testicular GCT includes chest and abdominal CT scans with contrast medium and serial determination of serum tumour markers AFP and beta unit of human chorionic gonadotropin (β -hCG) [1–4,13]. Interpretation of imaging is crucial. Small enlarged lymph-nodes may be wrongly interpreted as negative, and may determine an incorrect staging and thus inappropriate treatment. Although these imprecisions may hardly be a reason of prognostic variations in the short to medium term, they may induce further re-do treatments, which associate with a higher risk of late toxicity and late relapses. A multidisciplinary team of radiologists and clinicians must accurately evaluate imaging of the retroperitoneal space.
- 2) PeSCC. Staging includes palpation of inguinal nodes contextually or soon after surgery of the primary tumour. In case of non-palpable nodes, following an abdominal and pelvic CT/MRI scans with contrast medium, referral institutions have adopted the dynamic sentinel node biopsy (DSNB) [23,24]. This is a multistep procedure, which needs a dedicated team of urologists, radiologists, nuclear physicians and pathologists. The best results are achieved when each single step is correctly performed. A clinical data-set from the Dutch Cancer Institute, reported that patients with cN0 disease treated after 1994 showed improved cancer specific survival compared to those treated before 1994, when adjusting for pT category and grade [25,26]. Authors attributed this finding to the early detection of microscopic disease by DSNB, resulting in early lymph-node dissection in patients with a tumour positive sentinel node. Some evidences showing a trend towards a better survival in northern European countries have been reported [26]. These findings may support to refer patients with initial disease to high-volume experienced centres.

Surgical treatment of metastatic disease

The role of surgery remains crucial both in GCT and in PeSCC. The key surgery is lymph-node dissection, which takes places as prophylactic intervention, primary treatment or post-chemotherapy option according to stage.

1 GCT of the testis

- a) Prophylactic RPLND. Primary RPLND has been used in early stage non-seminomatous (NS) GCT of the testis for many years, but it has gradually lost its role [27]. In clinical stage I NS-GCT, the extremely favourable prognosis as well as the different therapeutic strategies with unaltered efficacy - even when they are delayed - led to a progressive reduction of the intensity of treatment and to an increasing role of tailored options. Currently, the recommended policies in these patients are active surveillance or adjuvant chemotherapy, consisting in one course of Bleomycin, Etoposide, Cisplatin (BEP), while RPLND is no longer suggested as first choice [1–4,13]. The reasons behind are the morbidity of surgery and, mostly, its low reproducibility on a large scale [28]. Mini-invasive RPLND (pure laparoscopic or robot assisted) has been introduced in order to reduce morbidity of open surgery [29]. Currently, the available evidences are consistent with a non-inferiority of mini-invasive RPLND in respect of open surgery [30–33]. However, RPLND - open or mini-invasive - remains a highly technical demanding procedure that requires experienced hands in referral centres, in order to achieve standardized levels of efficiency.
- b) Primary RPLND in early stage NS-GCT (stage II). RPLND represented the only effective therapeutic tool up to the introduction of effective chemotherapy, when the disease was limited to the retroperitoneum [32,34]. The chance of definitive cure depended on the burden of disease, which could vary from small volume (Stage IIA: < 2 cm), to very large disease (Stage II D: > 5 cm), where the chance of definitive cure was low [34]. Currently, indication of primary RPLND in stage II disease reduced, and currently is an option in small volume (Stage II A) disease with normal markers after orchiectomy. Other indications, as stage IIB non-seminoma or IIA/B seminoma, should be considered within clinical trials [1–4,13]. Expert opinions summarized by current guide-lines, recommend this surgery in experienced hands [1–4,13].
- c) Post-chemotherapy RPLND. Surgery is strongly indicated in case of a residual mass ≥ 1 cm and normalised markers following completion of primary chemotherapy in NSGCT [1–4,13]. Post-chemotherapy RPLND may be modulated, according to extent, volume, laterality and adhesion to other organs. A limited dissection in small and unilateral masses reduces the risk of retrograde ejaculation; a mini-invasive RPLND (pure laparoscopic or, with smaller experiences, robot-assisted) reduces the general morbidity of laparotomy [35]. On the other hand a maximal RPLND with contextual removal of organs involved by the disease and possible reconstructive surgery (e.g. vascular prosthesis or grafts) may increase the chance of cure in patients with gross masses infiltrating viscera or gross vessels [36]. This surgery is recommended in high-volume centres and should be performed by experienced hands. A better outcome following centralization of cure has been documented as far as in 1993 [37]. Considering 454 patients treated in West Scotland, year of diagnosis, extent of disease and treatment unit (the higher in volume Vs other 4), were all significant at regression analysis in predicting survival ($p < 0.001$). In a population-based study including 27,948 patients from 17 SEER registries (1998–2006), the 10-year testicular cancer mortality was derived according to different variables. Among 6192 patients with NSGCT, those who underwent RPLND had a 7-fold greater chance of survival than patients who had no RPLND ($p < 0.001$) at multivariable analysis [38]. A population study including 882 patients from (SEER database: 1988–1997), showed that the post-operative mortality increased as age and stage increased: 0.0%, 0.8% for regional, and 6.0% for metastatic disease ($p .001$) [39]. Authors

drew attention about the need of referring advanced cases to high-volume centres, where the reported mortality was lower (0% for primary and 0.8% for post-chemotherapy RPLND).

2 PeSCC

- a Prophylactic inguinal lymph-node dissection (ILND). Prophylactic ILND in case of clinically not palpable nodes (cNO) associates with a better disease control than ILND at relapse [40]. Nonetheless, ILND in stage N0, finds no more than 20% of patients with nodal disease, and associates with a significant morbidity, including lymphoedema and wound infections. Modified approaches, including template dissection, selection through individuation of risk category or DSNB, have been introduced, but require a specifically expertise, as already described for DSNB.
- b Primary inguino-iliac lymph-node dissection (IILND). This intervention is the key treatment in PeSCC, as nodal metastases represent the landmark of curability for metastatic disease. Actually, early small nodal metastases associate with a 5-year cure rate of 60%, while advanced or pelvic node metastases associate with not more than 30%, at the best [6–9]. Extent of inguinal dissection is formalised [7–9]. Pelvic dissection is generally recommended, and could be omitted in a subset of patients with a particularly favourable condition, according to studies performed in high-volume centres [41–43].
- c Post-chemotherapy IILND. These patients had undergone chemotherapy due to extent of disease or in the context of a clinical trial. Efficacy of chemotherapy prior to surgery has not definitively demonstrated [43]. The special set of application and the greater difficulties due to desmoplastic reaction due to chemotherapy advocate the need of expert surgeons in high-volume centres.

Population data in testicular and penile cancers

1 Survival analysis, time trends in population-based studies

a GCT of the testis

The EUROCORE-5 study included 56,397 patients recorded from 86 cancer registries (CRs), in the period 2000–2007, and followed up through 2008 in 29 countries [5]. Survival remained stable, and was high in most of the countries (around 90%). Nonetheless, the 5-year survival was low (<80%) in some Eastern countries. Older patients bearing a non-seminoma had the worse prognosis. A previous EUROCORE study [44] focusing on 10-yr survival and relapse pattern, evaluated 1,350 testicular cancer cases from 13 population-based CRs (1987–92) in 9 countries. According to stage distribution, three Eastern European countries had the lowest proportion of organ-confined disease at presentation. The 10-yr survival was statistically lower for seminoma in Estonia (63%) and in Poland (68%) than in referral CRs (two Northern Italian provinces: 90%), and for non-seminoma in Estonia (47% Vs 85%). Of interest, although relapses associated with survival, French CRs showed the highest relapse rates, but the 10-yr survival remained high (85% for seminoma and 83% for non-seminoma). These findings induced authors to hypothesize that in eastern European populations the lower survival was not due entirely to advanced stage at diagnosis, but also to inadequate treatment. The unfavourable effect of inadequate treatment on the outcome in testicular cancer, due to disparity in accessing cure, may be derived also by population studies over-sea. The aforementioned study from Fossa et al. [38] found that both ethnicity (white Vs non-white) and

educational level (a proxy of economic status) were associated with prognosis in patients with non-seminoma. The positive effect of accessing adequate health facilities can be derived from an English study, which evaluated data of patients aged 13–24 years treated during the period 1979–2001 by the National Cancer Intelligence Centre [45]. The relative survival for patients with testicular GCT increased from 84% to 96% between the first and last time period ($p < 0.001$), with a geographical variability that did not change after adjusting for deprivation index, used to mitigate the effect of economic income.

b PeSCC

Few datasets are available for penile cancer. The EUROCORE-5 study, analysing 10,935 patients from CRs, reported a stable survival during the study period from 1999 to 2007 [46]. Similarly, data from the US, confirmed no substantial time trend survival variation since 1990 in 450 patients from 9 SEER CRs [47]. Geographic differences of outcome, repeatedly reported by EUROCORE, was confirmed for epithelial tumours of penis also by the RARECAREnet project with the highest 5-year survival for the Northern (77%) and the lowest in the Eastern European countries (60%) [6]. The survival rate in northern Europe was assumed to depend on the introduction of early detection of inguinal lymph-node metastases through the introduction of DSNB, as reported above [25,26,41].

2 Conditional survival: a proxy of effective diagnosis and treatment?

The conditional survival is the probability to survive at five years being alive 1 or 3 years after diagnosis. This indicator may be a proxy of timely diagnosis and adequate treatment.

a GCT of the testis

Conditional survivals at 5 years, having survived the 1st year after diagnosis, were assessed from the EUROCORE dataset [5]. The 5 to 1-yr conditional relative survivals ranged between 95% and 97% in almost all areas and 92% in eastern European countries. As previously reported, we showed that in some Eastern countries initial stage was more advanced than in others. This observation may also imply that performance in treating patients in the first year could be suboptimal, probably due to more difficult accessibility to experienced centres.

PeSCC

From the EUROCORE-5 dataset a 5-yr survival of 68%, with a 1-year conditional survival of 80% are derived [5]. Considering conditional survivals figures, geographical differences markedly reduced. The greater increase between 5-year survival and conditional survival was however recognised for the Eastern European countries, indicating that many advanced and complex cases died during the first year after diagnosis.

3 Centralization and networking

a GCT of the testis

Dutch researchers, evaluating data between 1989 and 2009 from the Eindhoven Cancer Registry (ECR), reported an improvement of 5-yr relative survival in all the age-categories except for patients older than 60 years [48]. According to stage, a significant survival improvement was observed for seminoma with regional metastases: the 5-yr relative survival shifted from 93% in 1989–93 to 100% in 2004–9 ($p = 0.01$). Relevant improvement trends in 5-yr relative survival were recorded for metastatic non-seminoma and for metastatic seminoma, as they improved from 78% to 85% ($p = 0.05$), and from 73 to 88% ($p = 0.07$), respectively. The authors assumed that this was probably due to improved chemotherapy and to

the referral of patients with metastasized cancer to specialized centres as well as to the improvements of the post-chemotherapy RPLND, reasonably associated with centralization of more complex cases.

In 2006, the German Testicular Cancer Study Group started an evidence-based national second-opinion network in order to improve the care of testicular cancer patients: 1284 requests were submitted by 350 primary care physicians to the 31 s-opinion centres from November 2006 to October 2011 [49]. The first-opinion therapy suggested by the advice seeker was concordant with the second-opinion therapy recommended by the centres in 58% of the cases. Discordance between first and second opinions was found in 39.5%. Metastatic cases were those at lower concordance. The second-opinion treatment was less extensive in 28.1% and more extensive in 15.6% of the discordant cases than that originally planned. In another 56.3% of the cases, there was no substantial difference. Actual delivered treatment did not adhere with any opinion in as many as 30% of patients; 85% of the remaining underwent a treatment more adherent to second opinion. No data are available regarding outcomes.

The Italian Germ Cell Study Group (IGG) was founded in 2005 with the aims of spreading information regarding testis cancer, through a series of divulgation events, and improving the prognosis of patients, by sharing complex cases, addressing patients to high volume centres for highly specialized treatment [12]. Moreover, IGG promoted both patients lobbying in order to facilitate information and patients advocacy, in order to warrant patients rights in their work activities. A measurable effect was that of having improved the quality of histological reports of germ-cell tumours.

Recently, a position paper supporting the need of centralization has been released [50]. Authors recognize that it is impossible to find the highest evidence supporting improved outcomes on the basis of institutional volume alone, but indirect available data and expert consensus support improved outcomes in testicular cancer being achieved at high-volume centres and through collaborative groups. A call upon six interventions by all the stake-holders including clinicians, researchers, health-providers, payers, media operators and patients is proposed [50]. Hospital volume analysis was performed from the RARECAREnet in 7 European countries covered by registration [6]. Centralization of patients with testicular tumours was in general low during the period 2000–2007. Bulgarian registry showed that 75% of patients were treated in 19 different hospitals with a mean annual admission volume (MAV) for testicular tumour of 12 cases. Nonetheless, in Belgium and in the Netherlands, more centres (40 and 42, respectively) treated the 75% of patients with a MAV of 8 and 18, respectively. In these countries survival of testis cancer was high, regardless of the decentralisation and low MAV. This may depend on the presence of an effective network which permits to share patients according to a national management guide-lines and by the country public health investment for cancer.

b PeSCC

The Dutch experience probably offered the best example of how a leading centre (the National Cancer Institute in Amsterdam in this country), may favourably impact in a medium size country through its long experience in clinical practice and research [51]. Mortality gradually decreased from 1959 to 2006, and the percentage of missing stages decreased significantly from 15% in 1989–1994 to 9% in 2001–2006 ($p < 0.001$). These findings may be due to diagnostic anticipation and to the diffusion of effective staging procedures, mainly DSNB, which may favourably impact

the prognosis of PeSCC. Actually, according to the hospital volume analysis from the RARECAREnet data [6], centralization of PeSCC was very low in all the countries with the exception of the Netherlands and Slovenia.

Another positive example of networking is offered by the creation of networks specialized in penile cancer in UK. The experience of the supra-network multidisciplinary team in reviewing histology e redirecting treatment has been reported above [19]. In 2012, the first results of the network in the East Midlands in UK showed an increase in the number of cases discussed since its formation and a trend towards more conservative surgery [52].

Networking at EU level

As we argued, the management of testis and penile cancers poses significant diagnostic challenges, sometimes with major consequences for patients' quality of life and outcome. Medical expertise can be difficult to find because of the rarity of the diseases, and many patients may migrate from country to country in search of appropriate care. Inappropriate management may result in an increased risk of relapse, and risk of death due to cancer or other causes which can be treatment-related.

In order to improve patients referral across EU countries, at EU level the European Reference Networks (ERNs) have been established. The ERNs, three of which are specifically devoted to rare cancers, have been conceived by the EU Commission as a means to provide "highly specialized healthcare for rare or low-prevalence complex diseases". The ERN EURACAN covers all rare adult solid tumour cancers, grouping them into 10 domains corresponding to the RARECAREnet list. One of this domain is rare urological cancers and includes testicular cancer only.

The core business of ERNs is to provide multidisciplinary. In addition, the ERNs are meant to generate and disseminate knowledge on rare cancers, promote medical education and patient's information, produce clinical practice guidelines and foster research as well as epidemiological surveillance.

Conclusions

Population based studies showed survival differences across countries for these two rare cancers. It means that there is room for improvement thus for an European overall progress. The formal activation of ERNs is a cornerstone in the EU cooperation on rare cancers, and the Joint Action on rare Cancers (JARC) will be instrumental to make them grow up the best way possible. Actually, JARC aims at optimizing the process of creation of the ERNs, by providing them with operational solutions and professional guidance in the areas of quality of care, epidemiology, research and innovation, education and state of the art definition on prevention, diagnosis and treatment of rare cancers.

Funding

This research was partly funded by the European Commission through the Consumers, Health, Agriculture and Food Executive Agency (Chafea); Grant No. 2000111201; Information network on rare cancers-RARECARENet.

Conflicts of interest statement

None.

Appendix. RARECARENet Working Group

Monika Hackl (Austrian National Cancer Registry); Elizabeth Van Eycken, Kris Henau (Belgian Cancer Registry); Nadya Dimitrova (Bulgaria Cancer Registry); (Bulgarian Cancer Registry); Mario Sekerija (Croatian Cancer Registry); Ladislav Dušek (Czech National Cancer Registry); Margit Mägi (Estonian Cancer Registry); Nea Malila, Maarit Leinonen (Finnish Cancer Registry); Michel Velten (Bas Rhin Cancer Registry); Xavier Troussard (Basse Normandie Haematological malignancies Registry); Veronique Bouvier (Calvados Digestive Tract Registry); Anne-Valérie Guizard (Calvados, Registre Général des Tumeurs); Anne-Marie Bouvier (Côte d'Or Digestive Tract Registry, Burgundy); Patrick Arveux (Côte d'Or Gynaecologic Cancer registry); Marc Maynadié (Côte d'Or Haematological Malignancies Cancer Registry); Anne-Sophie Woronoff (Doubs Cancer Registry); Michel Robaszkiwicz (Finistère Digestive Tract Registry); Isabelle Baldi (Gironde CNS Tumour Registry); Alain Monnereau (Gironde Haematological Malignancies); Brigitte Tretarre (Hérault Cancer Registry); Marc Colonna (Isère Cancer Registry); Florence Molinié (Loire-Atlantique/Vendée Cancer Registry); Simona Bara (Manche Cancer Registry); Claire Schwartz (Marne & Ardennes, Thyroid); Bénédicte Lapôtre-Ledoux (Somme Cancer Registry); Pascale Grosclaude (Tarn Cancer Registry); Roland Stabenow (Berlin); Brandenburg; Mecklenburg-West Pomerania; Saxony; Saxony-Anhalt; Thüringen Cancer Registry); Sabine Luttmann (Bremen Cancer Registry, Leibniz Institute for Prevention Research and Epidemiology); Alice Nennecke (Hamburg Cancer Registry); Jutta Engel, Gabriele Schubert-Fritschle (Munich Cancer Registry); Jan Heidrich (North Rhine-Westphalia Cancer Registry); Bernd Holleczeck (Saarland Cancer Registry); Jón Gunnlaugur Jónasson (Icelandic Cancer Registry); Kerri Clough-Gorr, Harry Comber (National Cancer Registry Ireland); Guido Mazzoleni (Alto Adige Cancer Registry); Adriano Giacomini (Biella Cancer Registry); Antonella Suter Sardo (Catanzaro Cancer Registry); Alessandro Barchielli (Firenze-Prato Cancer Registry); Diego Serraino (Friuli Venezia Giulia, CRO Aviano National Cancer Institute); Roberta De Angelis, Sandra Mallone, Andrea Tavilla, Daniela Pierannunzio, Silvia Rossi, Mariano Santaquilani, Arnold Knijn (Istituto Superiore di Sanità, Rome); Fabio Panno (Latina Cancer Registry); Valerio Gennaro, Lucia Benfatto (Liguria Mesothelioma Registry); Paolo Ricci (Mantova Cancer Registry); Mariangela Autelitano (Milano Cancer Registry); Gianbattista Spagnoli (Modena Cancer Registry); Mario Fusco (Napoli 3 South Cancer Registry); Mario Usala (Nuoro Cancer Registry); Francesco Vitale (Palermo Cancer Registry); Maria Michiara (Parma Cancer Registry); Rosario Tumino (Ragusa Cancer Registry); Lucia Mangone (Reggio Emilia Cancer Registry); Fabio Falcini (Romagna Cancer Registry); Stefano Ferretti (RT Ferrara Cancer Registry); Rosa Angela Filiberti, Enza Marani (RTR Liguria, IRCCS AOU SM-IST); Arturo Iannelli (Salerno Cancer Registry); Flavio Sensi (Sassari Cancer Registry); Silvano Piffer, Maria Gentilini (Servizio Epidemiologia Clinica e Valutativa, Trento); Anselmo Madeddu, Antonio Ziino (Siracusa Cancer Registry); Sergio Maspero (Sondrio Cancer Registry); Pina Candela (Trapani Cancer Registry); Fabrizio Stracci (Umbria Cancer Registry); Giovanna Tagliabue (Varese Province Cancer Registry, Fondazione IRCCS Istituto Nazionale dei Tumori); Massimo Ruggie (Veneto Cancer Registry); Annalisa Trama, Gemma Gatta, Laura Botta, Riccardo Capocaccia (Fondazione IRCCS, National Cancer Institute, Milan); Santa Pildava (Latvian Cancer Registry); Giedre Smailyte (Lithuanian Cancer Registry); Neville Calleja (Malta National Cancer Registry, Health Information and Research); Tom Børge Johannesen (Norwegian Cancer Registry); Jadwiga Rachtan (Cracow Cancer Registry); Stanisław Gózdź (Kielce Cancer Registry); Jerzy Błaszczyk, Kamila Kępska (Lower Silesia (Wrocław); Cancer Registry); Gonçalo Forjaz de Lacerda (Açores Cancer

Registry); Maria José Bento (Northern Portugal Cancer Registry); Ana Miranda (Southern Portugal Cancer Registry); Chakameh Safaei Diba (Slovakian National Cancer Registry); Enrique Almar (Albacete. Castilla-La Mancha Cancer Registry); Nerea Larrañaga, Arantza Lopez de Munain (Basque Country Cancer Registry); Ana Torrella-Ramos (Castellón-Valencia (breast); Cancer Registry); José María Díaz García (Cuenca Cancer Registry); Rafael Marcos-Gragera (Girona Cancer Registry); Maria José Sanchez (Granada Cancer Registry, CIBERESP, iberGranada); Carmen Navarro, Diego Salmeron (Murcia Cancer Registry, CIBERESP, IMIB-Arixaca); Conchi Moreno-Iribas (Navarra Cancer Registry, CIBERESP); Jaume Galceran, Marià Carulla (Tarragona Cancer Registry); Mohsen Mousavi (Basel Cancer Registry); Christine Bouchardy (Geneva Cancer Registry); Silvia M. Ess (Grisons-Glarus, St. Gallen Cancer Registry); Andrea Bordoni (Ticino Cancer Registry); Isabelle Konzelmann (Valais Cancer Registry); Jem Rashbass (Public Health England); Anna Gavin (Northern Ireland Cancer Registry); David H Brewster (Scotland Cancer Registry); Dyfed Wyn Huws (Welsh Cancer Intelligence and Surveillance Unit); Otto Visser (The Netherlands Cancer Registry); Magdalena Bielska-Lasota (National Institute of Public Health-NIH, Warszawa); Maja Primic-Zakelj (Cancer Registry of Republic of Slovenia); Ian Kunkler (Edinburgh Cancer Centre, University of Edinburgh); Ellen Benhamou (Institut de Cancérologie Gustave Roussy, Villejuif, France).

References

- [1] Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, et al. European association of urology. Guidelines on testicular cancer: 2015 update. *Eur Urol* 2015 Dec;68(6):1054–68.
- [2] Beyer J, Albers P, Altner R, Aparicio J, Bokemeyer C, Busch J, et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. *Ann Oncol* 2013 Apr;24(4):878–88.
- [3] Oldenburg J, Fossa SD, Nuver J, Heidenreich A, Schmolli HJ, Bokemeyer C, et al. ESMO guidelines working group. Testicular seminoma and non-seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2013 Oct;24(Suppl. 6). vi125–32.
- [4] NCCN Clinical Practice Guideline in Oncology. Testicular cancer, v. 2. 2017. https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf. [Accessed 3 April 2017].
- [5] Trama A, Foschi R, Larrañaga N, Sant M, Fuentes-Raspall R, Serraino D, et al. EUROCORE-5 Working Group. Survival of male genital cancers (prostate, testis and penis) in Europe 1999–2007: results from the EUROCORE-5 study. *Eur J Cancer* 2015 Oct;51(15):2206–16.
- [6] Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E, et al. RARECAREnet working group. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-apopulation-based study. *Lancet Oncol* 2017 Aug;18(8):1022–39.
- [7] NCCN Clinical Practice Guideline in Oncology. Penile cancer, v. 2. 2017. https://www.nccn.org/professionals/physician_gls/pdf/penile.pdf. [Accessed 31 July 2017].
- [8] Ornellas AA. Management of penile cancer. *J Surg Oncol* 2008;97(3):199–200.
- [9] Protzel C, Alcaraz A, Horenblas S, Pizzocaro G, Zlotta A, Hakenberg OW. Lymphadenectomy in the surgical management of penile cancer. *Eur Urol* 2009;55(5):1075–88.
- [10] Verrill C, Yilmaz A, Srigley JR, Amin MB, Compérat E, Egevad L, et al. Members of the international society of urological pathology testicular tumor panel. Reporting and staging of testicular germ cell tumors: the international society of urological pathology (ISUP) testicular cancer consultation conference recommendations. *Am J Surg Pathol* 2017 Jun;41(6):e22–32.
- [11] Nicolai N, Colecchia M, Biondi D, Catanzaro M, Stagni S, Torelli T, et al. Concordance and prediction ability of original and reviewed vascular invasion and other prognostic parameters of clinical stage I nonseminomatous germ cell testicular tumors after retroperitoneal lymph node dissection. *J Urol* 2011;186:1298–302.
- [12] De Giorgi U, Nicolai N, Tana S, Tavolini IM, Palazzi S, Bracarda S, et al. Italian Germ Cell Cancer Group. IGG practice guidelines on germ cell tumor in adult male patients. *Tumori* 2008 Jan-Feb;94(1):96–109.
- [13] Dieckmann KP, Frey U, Lock G. Contemporary diagnostic work-up of testicular germ cell tumours. *Nat Rev Urol* 2013;7(3):703–12.
- [14] Fabiani A, Filosa A, Pieramici T, Mammanna G. Testicular nodules suspected for malignancy. Does the pathologist make the difference for organ-sparing surgery? *Anal Quant Cytopathol Histopathol* 2015 Jun;37(3):147–52.
- [15] Mikuz G, Colecchia M. Teratoma with somatic-type malignant components of the testis. A review and an update. *Virchows Arch* 2012 Jul;461(1):27–32.

- [16] Giannatempo P, Pond GR, Sonpavde G, Albany C, Lorient Y, Sweeney CJ, et al. Treatment and clinical outcomes of patients with teratoma with somatic-type malignant transformation: an International collaboration. *J Urol* 2016 Jul;196(1):95–100.
- [17] Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital Organs-Part A: renal, penile, and testicular tumours. *Eur Urol* 2016 Jul;70(1):93–105.
- [18] Chaux A, Reuter V, Lezcano C, Velazquez EF, Torres J, Cubilla AL. Comparison of morphologic features and outcome of resected recurrent and nonrecurrent squamous cell carcinoma of the penis: a study of 81 cases. *Am J Surg Pathol* 2009 Sep;33(9):1299–306.
- [19] Tang V, Clarke L, Gall Z, Shanks JH, Nonaka D, Parr NJ, et al. Should centralized histopathological review in penile cancer be the global standard? *BJU Int* 2014 Sep;114(3):340–3.
- [20] Giannarini G, Dieckmann KP, Albers P, Heidenreich A, Pizzocaro G. Organ-sparing surgery for adult testicular tumours: a systematic review of the literature. *Eur Urol* 2010 May;57(5):780–90.
- [21] Hegarty PK, Eardley I, Heidenreich A, McDougal WS, Minhas S, Spiess PE, et al. Penile cancer: organ-sparing techniques. *BJU Int* 2014 Dec;114(6):799–805.
- [22] Djajadiningrat RS, van Werkhoven E, Meinhardt W, van Rhijn BW, Bex A, van der Poel HG, et al. Penile sparing surgery for penile cancer-does it affect survival? *J Urol* 2014 Jul;192(1):120–5.
- [23] Lam W, Alnajjar HM, La-Touche S, Perry M, Sharma D, Corbishley C, et al. Dynamic sentinel lymph node biopsy in patients with invasive squamous cell carcinoma of the penis: a prospective study of the long-term outcome of 500 inguinal basins assessed at a single institution. *Eur Urol* 2013 Apr;63(4):657–63.
- [24] Nicolai N. Has dynamic sentinel node biopsy achieved its top performance in penile cancer? What clinicians still need to manage lymph nodes in early stage penile cancer. *Eur Urol* 2013 Apr;63(4):664–6.
- [25] Djajadiningrat RS, Graafland NM, van Werkhoven E, Meinhardt W, Bex A, van der Poel HG, et al. Contemporary management of regional nodes in penile cancer-improvement of survival? *J Urol* 2014 Jan;191(1):68–73.
- [26] Bray F, Klint A, Gislum M, Hakulinen T, Engholm G, Tryggvadóttir L, et al. Trends in survival of patients diagnosed with male genital cancers in the Nordic countries 1964–2003 followed up until the end of 2006. *Acta Oncol* 2010;49(5):644–54.
- [27] Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihler R. Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer. Review of the Indiana University experience 1965–1989. *Br J Urol* 1993 Mar;71(3):326–35.
- [28] Albers P, Siener R, Krege S, Schmelz HU, Dieckmann KP, Heidenreich A, et al., German Testicular Cancer Study Group. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. *J Clin Oncol* 2008 Jun 20;26(18):2966–72.
- [29] Rassweiler JJ, Scheitlin W, Heidenreich A, Laguna MP, Janetschek G. Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective. *Eur Urol* 2008 Nov;54(5):1004–15.
- [30] Kunit T, Janetschek G. Minimally invasive retroperitoneal lymphadenectomy: current status. *Urol Clin North Am*. 2015 Aug;42(3):321–9.
- [31] Pearce SM, Golan S, Gorin MA, Luckenbaugh AN, Williams SB, Ward JF, et al. Safety and early oncologic effectiveness of primary robotic retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer. *Eur Urol* 2017 Mar;71(3):476–82.
- [32] Nicolai N, Tarabelloni N, Gasperoni F, Catanzaro M, Stagni S, Torelli T, et al. Laparoscopic retroperitoneal lymph node dissection in clinical stage I non-seminomatous germ cell tumors of the testis: safety and efficacy analyses at a high volume center. *J Urol* 2017 Sep 28. <https://doi.org/10.1016/j.juro.2017.09.088> [Epub ahead of print].
- [33] Jacobsen NE, Foster RS, Donohue JP. Retroperitoneal lymph node dissection in testicular cancer. *Surg Oncol Clin N Am*. 2007 Jan;16(1):199–220.
- [34] Pizzocaro G, Zanoni F, Milani A, Piva L, Salvioni R, Pasi M, et al. Retroperitoneal lymphadenectomy and aggressive chemotherapy in non bulky clinical Stage II nonseminomatous germinal testis tumors. *Cancer* 1984 Mar 15;53(6):1363–8.
- [35] Nicolai N, Cattaneo F, Biasoni D, Catanzaro M, Torelli T, Zazzara M, et al. Laparoscopic postchemotherapy retroperitoneal lymph-node dissection can be a standard option in defined nonseminomatous germ cell tumor patients. *J Endourol* 2016 Oct;30(10):1112–9.
- [36] Heidenreich A, Haidl F, Paffenholz P, Pape C, Neumann U, Pfister D. Surgical management of complex residual masses following systemic chemotherapy for metastatic testicular germ cell tumours. *Ann Oncol* 2017 Feb 1;28(2):362–7.
- [37] Harding MJ, Paul J, Gillis CR, Kaye SB. Management of malignant teratoma: does referral to a specialist unit matter? *Lancet* 1993 Apr 17;341(8851):999–1002.
- [38] Fossa SD, Cvancarova M, Chen L, Allan AL, Oldenburg J, Peterson DR, et al. Adverse prognostic factors for testicular cancer-specific survival: a population-based study of 27,948 patients. *J Clin Oncol* 2011 Mar 10;29(8):963–70.
- [39] Capitanio U, Jeldres C, Perrotte P, Isbarn H, Crépel M, Cloutier V, et al. Population-based study of perioperative mortality after retroperitoneal lymphadenectomy for nonseminomatous testicular germ cell tumors. *Urology* 2009 Aug;74(2):373–7.
- [40] Ornellas AA, Seixas AL, de Moraes JR. Analyses of 200 lymphadenectomies in patients with penile carcinoma. *J Urol* 1991;146:330–2.
- [41] Nicolai N, Catanzaro M, Zazzara M. The role of surgery in metastatic squamous cell carcinoma of the penis. *Curr Opin Urol* 2016 Nov;26(6):596–601.
- [42] Lughezzani G, Catanzaro M, Torelli T, Piva L, Biasoni D, Stagni S, et al. The relationship between characteristics of inguinal lymph nodes and pelvic lymph node involvement in penile squamous cell carcinoma: a single institution experience. *J Urol* 2014 Apr;191(4):977–82.
- [43] Nicolai N, Sangalli LM, Necchi A, Giannatempo P, Paganoni AM, Colecchia M, et al. A combination of cisplatin and 5-fluorouracil with a taxane in patients who underwent lymph node dissection for nodal metastases from squamous cell carcinoma of the penis: treatment outcome and survival analyses in neoadjuvant and adjuvant settings. *Clin Genitourin Cancer* 2016 Aug;14(4):323–30.
- [44] Sant M, Aareleid T, Artioli ME, Berrino F, Coebergh JW, Colonna M, et al. Ten-year survival and risk of relapse for testicular cancer: a EURO CARE high resolution study. *Eur J Cancer* 2007 Feb;43(3):585–92.
- [45] Geraci M, Eden TO, Alston RD, Moran A, Arora RS, Birch JM. Geographical and temporal distribution of cancer survival in teenagers and young adults in England. *Br J Cancer* 2009 Dec 1;101(11):1939–45.
- [46] Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, et al., RARECARE working group. Rare cancers are not so rare: the rare cancer burden in Europe. *Eur J Cancer* 2011 Nov;47(17):2493–511.
- [47] Verhoeven RH, Janssen-Heijnen ML, Saum KU, Zanetti R, Caldarella A, Hollecck B, et al. EUNICE Survival Working Group Population-based survival of penile cancer patients in Europe and the United States of America: no improvement since 1990. *Eur J Cancer* 2013 Apr;49(6):1414–21. <https://doi.org/10.1016/j.ejca.2012.10.029> [Epub 2012 Dec 8].
- [48] Verhoeven RH, Karim-Kos HE, Coebergh JW, Brink M, Horenblas S, de Wit R, et al. Markedly increased incidence and improved survival of testicular cancer in The Netherlands. *Acta Oncol* 2014 Mar;53(3):342–50. <https://doi.org/10.3109/0284186X.2013.819992>.
- [49] Zengerling F, Hartmann M, Heidenreich A, Krege S, Albers P, Karl A, et al., GTC SG (German Testicular Cancer Study Group). German second-opinion network for testicular cancer: sealing the leaky pipe between evidence and clinical practice. *Oncol Rep* 2014 Jun;31(6):2477–81.
- [50] Tandstad T, Kollmannsberger CK, Roth BJ, Jeldres C, Gillessen S, Fizazi K, et al. Practice makes perfect: the rest of the story in testicular cancer as a model curable neoplasm. *J Clin Oncol* November 1 2017;35(31):3525–8.
- [51] Graafland NM, Verhoeven RH, Coebergh JW, Horenblas S. Incidence trends and survival of penile squamous cell carcinoma in The Netherlands. *Int J Cancer* 2011 Jan 15;128(2):426–32.
- [52] Kumar P, Singh S, Goddard JC, Terry TR, Summerton DJ. The development of a supranational network for the management of penile cancer. *Ann R Coll Surg Engl* 2012 Apr;94(3):204–9.